本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
A third Cambridge Checkpoint test series to be introduced worldwide from March 2026 Entries for primary school tests rise by 13% and by 9% for lower secondary school CAMBRIDGE, England, Feb. 18, 2025 /PRNewswire/ -- The International Education group at Cambridge University Press & Assessment (Cambridge), today announced an expansion of its series of Cambridge Checkpoint tests, valued for their role in helping schools identify the learning needs of primary and lower secondary students. Over 1600 schools in 101 countries used Cambridge Checkpoint tests last year to obtain an international benchmark of their learners' performance and Cambridge is introducing a third test series in March, as a further option to those in May and October, from 2026 to meet rising global demand. It is also introducing a one-week timetable for each series and moving the May series to a later date to better suit the needs of schools. Student from Marina Regina School Indonesia Cambridge Checkpoint tests assess progress in Mathematics, English and Science and are typically taken by learners at the end of Cambridge Primary (age 10 to 11) or Lower Secondary education (age 13 to 14). The tests are marked by Cambridge examiners and each school receives a diagnostic feedback report to help monitor individual and group performance. The reports enable schools to make informed decisions about their learners' needs and understand how their learners have performed compared with Cambridge International Schools around the world. Demand for Cambridge Checkpoint tests has been increasing in line with the growth in international education. Cambridge received over 300,000 entries for Cambridge Primary and Lower Secondary Checkpoint in 2024, with entries for the primary tests up 13% and entries for lower secondary tests up 9% on 2023. Reflecting the growth in demand, entries for Cambridge Primary Checkpoint tests surpassed those for Lower Secondary Checkpoint last year, with entries from schools in Indonesia increasing by 14% and Malaysia by 19%. The timetable changes are a direct response to feedback from schools, particularly in Southeast Asia & Pacific, South Asia and MENA, who wanted the Cambridge Checkpoint test series to align better with the end of their school year. Kristine T. Amador, Cambridge Primary Coordinator at Mentari Intercultural School Bintaro, Indonesia said: "At Mentari Intercultural School Bintaro, implementing the Cambridge Primary Checkpoint assessments has proven incredibly beneficial in tracking and understanding each student's academic progress. Detailed feedback empowers our educators and students alike to focus on key areas for improvement. These assessments can support global learners, offering a consistent benchmark for academic achievement across diverse educational contexts." Rod Smith, Group Managing Director for International Education at Cambridge said: "Cambridge Checkpoint tests play a crucial role in helping schools track young learner progress and tailor support effectively. Responding to an increased demand from our community, the introduction of a third test series gives more schools the flexibility to test students at a time that best fits their academic schedule, ensuring they get the most from this valuable assessment tool. I am grateful to all the schools who helped us shape these changes with their valuable feedback." A Cambridge research study found that schools adopting Cambridge Lower Secondary Checkpoint had a small but significant improvement in their average Cambridge IGCSE grade, compared to schools not adopting Cambridge Checkpoint. The study also showed that Cambridge Lower Secondary Checkpoint scores were a good predictor of performance in Cambridge IGCSEs, particularly in the same or a related subject. About Cambridge Cambridge University Press & Assessment is part of the University of Cambridge. Our International Education group works with schools worldwide to build an education that shapes knowledge, understanding and skills. Together, we give learners the confidence they need to thrive and make a positive impact in a changing world. We offer a globally trusted and flexible framework for education from age 3 to 19 (the Cambridge Pathway), informed by research, experience, and listening to educators. With recognised qualifications (such as Cambridge IGCSE and International AS & A Level), high-quality resources, comprehensive support and valuable insights, we help schools prepare every student for the opportunities and challenges ahead. Together, we help Cambridge learners be ready for the world. Learn more at www.cambridgeinternational.org
MORRISVILLE, NC., July 8, 2024 /PRNewswire/ -- Immorna Biotherapeutics, Inc. (Immorna), a clinical stage biotechnology company developing both self-replicating and conventional mRNA-based therapeutics and vaccines, announced today that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for JCXH-211 intravenous (IV), a novel, first-in-class self-replicating mRNA (srRNA) encoding the engineered human interleukin (IL)-12 protein. The IND clearance allows Immorna to initiate a Phase 1/2, multi-center, open-label, dose escalation and expansion study of JCXH-211 administered intravenously in patients with malignant solid tumors. The goal of the study is to assess safety and tolerability, determine the recommended Phase 2 dose (RP2D) for JCXH-211 IV in combination with checkpoint inhibitor (CPI), and assess preliminary efficacy of the combination at the RP2D. "We are excited to have achieved this important milestone for one of our key assets," said NgocDiep Le, M.D., Ph.D., President and Global Chief Medical Officer of Immorna. Based on data from our preclinical studies, clinical data from our JCXH-211 intratumoral administration (IT) trial, and the candidate drug's mechanism of action, we believe JCXH-211 IV in combination with CPI has the potential to work synergistically to enhance anti-tumor effect. We look forward to working with the investigators and patients to bring this potential novel therapy to patients who are in dire need of new and effective treatments." JCXH-211 is a first-in-class lipid nanoparticle (LNP) encapsulated srRNA, using Immorna's proprietary technology, encoding the engineered human IL-12 protein. In multiple preclinical animal and patient-derived xenograft (PDX) models, the anti-viral innate response triggered by RNA replicon together with the potent anti-cancer immunity stimulated by IL-12 conferred JCXH-211 superior tumor-eradicating potency, which was better than similar preclinical candidates employing conventional (non-replicating) mRNA. Interim data from a Phase 1 trial of JCXH-211 IT monotherapy has demonstrated excellent safety, tolerability and significant anti-tumor biological activities, including abscopal effect. IL-12 is a naturally occurring cytokine that plays a key role in the body's immune response against cancer. Despite consistently showing potent antitumor activity in preclinical studies, recombinant IL-12 protein treatment at tolerable doses in humans failed to provide clinical benefit. One key challenge for IL-12 protein treatment is the non-overlap of tolerability window and therapeutic window. Recombinant IL-12 is unstable in vivo and have a very short half-life, and frequent intravenous administration of recombinant human IL-12 protein was challenging due to unacceptable toxicities. Thanks to the intrinsic feature of our srRNA technology, JCXH-211 IV enables a prolonged expression of IL-12 preferentially in tumor tissues rather than normal tissues, leading to modulation of tumor microenvironment and activation of antitumor immune responses, while minimizing systemic toxicity. JCXH-211-IV demonstrated excellent safety profile in nonclinical studies using rodents and non-human primates. If successful, JCXH-211 IV may become another lifesaving yet easily accessible therapy for cancer patients who have progressed on or are resistant to currently available treatments. More information can be found at www.immorna.com. About ImmornaImmorna is a rapidly expanding biotechnology company, focusing on the development of RNA-based therapeutics and vaccines. Immorna is utilizing multiple RNA platforms, including conventional, self-replicating and circular RNAs. Since its founding in 2019, Immorna has built a robust CMC platform for RNA synthesis, purification, and analytical testing that is well suited for clinical and commercial development. In addition, with its state-of-the-art screening tools, Immorna has developed an arsenal of RNA delivery vehicles, including polymers and lipid nanoparticles featuring multiple proprietary ionizable cationic lipids suitable for intramuscular, intravenous and tissue-targeting delivery. Immorna has a growing intellectual property portfolio and a diverse RNA development pipeline spanning cancer immunotherapy, infectious diseases, rare genetic diseases, and medical cosmetology, and quickly advancing its oncology drug and infectious disease vaccine candidates into clinical stages. Website: www.immorna.com
- A new study published in the Journal for ImmunoTherapy of Cancer (JITC) shows that Lunit's AI-powered biomarker "Lunit SCOPE IO" can predict favorable outcomes of Inflamed Immune Phenotype patients treated with Immune Checkpoint Inhibitor across multiple cancer types SEOUL, South Korea, Feb. 16, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a groundbreaking study published in the Journal for ImmunoTherapy of Cancer (JITC). The study demonstrates the ability of Lunit SCOPE IO, to enable quantitative immune phenotyping from H&E stained slides as a broadly accessible biomarker for immunotherapy. Lunit's AI-powered biomarker "Lunit SCOPE IO" The study, conducted on a real-world multicenter cohort of 1,806 Immune Checkpoint Inhibitor (ICI)-treated patients across 27 tumor types, showcases a correlation between the Inflamed Immune Phenotype and positive ICI treatment responses. There is an unmet need for improved immunotherapy biomarkers, and this study highlights the importance of Lunit SCOPE IO's ability to quantify immune phenotype (IP) as Inflamed, Excluded, or Desert, purely from H&E whole slide images (WSIs). Utilizing advanced machine learning (ML) models, Lunit SCOPE IO segments tissue into cancer area (CA) and cancer stroma (CS) within WSIs. The model also detects Tumor-Infiltrating Lymphocytes (TILs) using a cell detection model trained on over 17,000 WSIs spanning multiple solid tumor types. Based on TIL density, the model classifies the tumor into one of three immune phenotypes: Inflamed (IIP; high TIL density within CA), Immune Excluded (IEP; TILs within CS but excluded from CA), and Immune Desert (IDP; low TIL density within both CA and CS). In an independent real-world dataset of ICI-treated patients, Lunit SCOPE IO demonstrated predictive power for clinical outcomes, including objective response rates (ORR), progression-free survival (PFS), and overall survival (OS). In the study, IIP patients showed significantly favorable clinical outcomes post-ICI treatment. More favorable ORRs (26.3% vs 15.8%), prolonged PFS (5.3 vs. 3.1 months) and OS (25.3 vs. 13.6 months) were observed in IIP patients, irrespective of ICI regimen or programmed death-ligand 1 (PD-L1) expression. The dataset reflected global diversity, with data coming from Stanford University, Samsung Medical Center, Seoul National University Bundang Hospital, Chonnam National University Hospital, and Northwestern Memorial Hospital, and more. This study paves the way for more precise patient selection with a time-efficient and labor-efficient analysis at scale in immunotherapy. Lunit plans to further validate and deploy Lunit SCOPE IO, ultimately enabling more personalized and effective immunotherapy strategies, especially under the current limitations of traditional biomarkers. "This study marks a major step towards better biomarkers for immunotherapy driven by AI, analyzing the tumor microenvironment to determine immune phenotype quantitatively and predict patient responses to ICI therapy," said Brandon Suh CEO of Lunit. "Our commitment to advancing cancer care through innovation has never been clearer. By providing a robust tool for personalized treatment strategies, Lunit SCOPE IO promises improved outcomes and could redefine the standard of care for patients in several cancer types where predictive biomarkers are lacking."Published in the JITC, the official journal of the Society for Immunotherapy of Cancer (SITC), the study also contributes to SITC's mission of enhancing cancer patient outcomes by advancing the science and application of cancer immunotherapy. SITC is the world's leading member-driven organization that includes over 4,650 members from 35 medical specialties across 63 countries worldwide. About Lunit Founded in 2013, Lunit is a deep learning-based medical AI company on a mission to conquer cancer. We are committed to harnessing AI to ensure accurate diagnosis and optimal treatment for each cancer patient using AI-powered medical image analytics and AI biomarkers. As a medical AI company grounded on clinical evidence, our findings are presented in major peer-reviewed journals, such as the Journal of Clinical Oncology and the Lancet Digital Health, and global conferences, including ASCO and RSNA. After receiving FDA clearance and the CE Mark, our flagship Lunit INSIGHT suite is clinically used in approximately 3,000+ hospitals and medical institutions across 40+ countries. Lunit is headquartered in Seoul, South Korea, with offices and representatives worldwide. For more information, please visit lunit.io. About Lunit SCOPE Lunit SCOPE is a suite of AI-powered software that analyzes tissue slide images for digital pathology and AI biomarker development, aiming to optimize workflow and facilitate more accurate and predictive clinical data for clinicians and researchers. Lunit SCOPE platform offers multiple AI-powered tissue analysis products and assays that can streamline digital pathology workflow and diagnostics and enhance the drug development process. Lunit SCOPE IO analyzes the tumor microenvironment (TME) based on H&E analysis and provides AI-based predictive clinical outcome information. In addition, AI-driven Immunohistochemistry (IHC) slide analysis services are offered through products such as Lunit SCOPE PD-L1, Lunit SCOPE HER2, Lunit SCOPE ER/PR, and others.
SHANGHAI, Jan. 31, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative therapies for the treatment of hematologic malignancies and solid tumors, has announced CARsgen's execution of a collaboration agreement with F. Hoffmann-La Roche Ltd ("Roche") to evaluate CARsgen's investigational drug AB011, the first humanized monoclonal antibody against Claudin18.2 (CLDN18.2) that received IND clearance globally, in combination with atezolizumab, Roche's PD-L1 checkpoint inhibitor, along with standard-of-care chemotherapy in patients with gastric or gastroesophageal junction carcinoma . Under the terms of the agreement, Roche will be responsible for operation and conduct of the trial while both companies co-share the costs of the AB011 treatment arms in the study. As part of the clinical collaboration, CARsgen's proprietary CLDN18.2 IHC test kit, which has showed excellent specificity and sensitivity profiles, will be applied to evaluate CLDN18.2 expression in the gastric cancer patients. The co-funded study of AB011 in combination with atezolizumab will be conducted as part of Roche's Morpheus Platform. The Morpheus Platform is a collection of Phase Ib/II clinical trials in multiple cancers with high unmet clinical needs including gastrointestinal cancer, designed to assess the safety and early efficacy to enable more rapid and efficient development of novel cancer treatment combinations. "We are glad to work with Roche, a global leader in oncology, to explore the potential of AB011 in combination with atezolizumab and chemotherapy for the treatment of gastric cancer," said Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen, "Gastric cancer is one of the most common cancer types worldwide and the treatment options for gastric cancer patients are still very limited. CLDN18.2 is a promising therapeutic target for the treatment of CLDN18.2 positive solid tumors, including gastric cancer, pancreatic cancer, etc. Since 2014, CARsgen team has developed several innovative medicines against CLDN18.2 in the pipeline including CAR T-cell therapies and AB011. AB011 is an important asset in the CLDN18.2 franchise of CARsgen and is the first monoclonal antibody against CLDN18.2 that received IND clearance in China. Through this collaboration, we are excited to evaluate the combination of AB011 and atezolizumab which can potentially bring greater clinical benefits to gastric cancer patients." About AB011 AB011 is a humanized Claudin18.2 monoclonal antibody (mAb) product that has received an investigational new drug (IND) approval from the National Medical Products Administration (NMPA) for the treatment of Claudin18.2 positive solid tumors. CARsgen is conducting a Phase I clinical trial of AB011 for the treatment of Claudin18.2 positive solid tumors in China to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of AB011 infusion. About CARsgen CARsgen is a biopharmaceutical company with operations in China and the U.S. and is focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. CARsgen has built an integrated cell therapy platform with in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. CARsgen's vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable. Contact Us For more information, please visit https://www.carsgen.com/
SAN FRANCISCO and SUZHOU, China, Feb. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that its first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, IBI363, has received its second Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA). This designation applies to the treatment of unresectable, locally advanced, or metastatic squamous non-small cell lung cancer (sqNSCLC) that has progressed following anti-PD-(L)1 immune checkpoint inhibitor therapy and platinum-based chemotherapy. IBI363 has demonstrated encouraging efficacy and safety across multiple solid tumor types. Currently, Innovent is conducting Phase 1/2 clinical trials of IBI363 mainly in China and the U.S. At the World Conference on Lung Cancer (WCLC) in September 2024, IBI363 presented promising efficacy signals in patients with sqNSCLC who had previously received immunotherapy: In the 3 mg/kg dose group, among patients with at least 12 weeks of follow-up or study completion (n=18), the objective response rate (ORR) was 50.0%, and the disease control rate (DCR) was 88.9%. The median progression-free survival (PFS) has not yet been reached and remains under follow-up. In the 1/1.5 mg/kg dose group, the median PFS was 5.5 months (95% CI: 1.5, 8.3), with a 12-month PFS rate of 30.7%, highlighting the potential long-term benefits of immunotherapy. Across the 1/1.5/3 mg/kg dose groups, patients with PD-L1 TPS<1% (n=22) and those with PD-L1 TPS≥1% (n=22) achieved encouraging ORRs of 36.4% and 31.8%, respectively, suggesting IBI363's potential advantage in PD-L1 low-expression populations. Dr. Hui Zhou, Senior Vice President of Innovent, stated, "We are pleased that IBI363 has been granted Fast Track Designation by the FDA for sqNSCLC, following its previous designation for melanoma. Earlier, we reported that in an expanded cohort of sqNSCLC patients, IBI363 showed a trend toward improved ORR and DCR at higher doses, along with a manageable safety profile. The latest PFS data from the 3 mg/kg dose group after longer follow-up further strengthens our confidence in IBI363's potential as an immunotherapy offering long-term benefits to patients. We will present the relevant data at upcoming academic conferences this year. More encouragingly, IBI363 has demonstrated potent anti-tumor activity regardless of PD-L1 expression levels. This suggests that IBI363 may not only advance treatment for immunotherapy-resistant populations but also for cold tumors with low or no PD-L1 expression. In addition to lung cancer, we have observed encouraging efficacy signals in cold tumors, including colorectal cancer and mucosal melanoma, with melanoma already advancing to pivotal clinical stages. Moving forward, we will continue to explore IBI363 in early-line treatment and in combination therapies." Fast Track Designation (FTD) is a regulatory process designed to expedite the clinical development and review of drugs intended to treat serious conditions and address unmet medical needs. Drug candidates granted FTD benefit from increased communication with the FDA throughout subsequent drug development, potentially accelerating their clinical development and approval process. About IBI363 (First-in-class PD-1/IL-2α-bias bispecific antibody fusion protein)) IBI363 is a first-in-class drug candidate independently developed by Innovent Biologics. It is a PD-1/IL-2 bispecific antibody fusion protein designed to enhance efficiency while minimizing toxicity. The IL-2 arm of IBI363 has been engineered to optimize therapeutic effects with reduced side effects, while the PD-1 binding arm enables PD-1 blockade and selective IL-2 delivery. By simultaneously inhibiting the PD-1/PD-L1 pathway and activating the IL-2 pathway, IBI363 facilitates more precise and efficient targeting and activation of tumor specific T cells. Preclinical studies have shown that IBI363 exhibits strong anti-tumor activity across multiple tumor-bearing pharmacological models, including those resistant to PD-1 inhibitors and metastatic models. Additionally, it has demonstrated a favorable safety profile in preclinical models. Clinical trials are currently underway in China, the United States, and Australia to evaluate its safety, tolerability and preliminary efficacy in subjects with advanced malignancies. About Squamous Non-Small Cell Lung Cancer (sqNSCLC) Lung cancer is the most common and deadliest malignancy worldwide, including in China[1], posing a significant public health challenge. Non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancer cases[2], with squamous cell carcinoma being one of its two major subtypes[2]. In recent years, immune checkpoint inhibitors have transformed the treatment landscape for NSCLC. However, for patients with NSCLC who have failed immunotherapy and lack driver gene mutations, there remains a significant and urgent unmet need for effective treatment options. The standard second- or third-line treatment, docetaxel, offers limited efficacy, with a median progression-free survival (PFS) of less than four months[3],[4]. While antibody-drug conjugates (ADCs) have shown promise, two large Phase 3 studies in squamous NSCLC have yet to demonstrate satisfactory efficacy[3],[4]. About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 14 products in the market. It has 3 new drug applications (NDA) under regulatory review, 3 assets in Phase III or pivotal clinical trials and 17 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn. Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s). Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. References: 1 Globocan 2022 (version 1.1) - 08.02.2024 2 NCCN guidelines (NSCLC, version 3.2025) 3 J Clin Oncol . 2025 Jan 20;43(3):260-272. doi: 10.1200/JCO-24-01544. 4 J Clin Oncol . 2024 Aug 20;42(24):2860-2872. doi: 10.1200/JCO.24.00733.
HONG KONG, Feb. 13, 2025 /PRNewswire/ -- Regal Hotels International is leveraging its extensive hotel network to launch the exclusive "Long-stay Accommodation Programme" for Hospital Authority (HA) staff. In response to the increasing demand for public healthcare services, the HA has been proactively recruiting both locally and non-locally trained healthcare professionals. Recognising the accommodation needs of these healthcare professionals, this initiative aims to provide additional accommodation options for HA employees, demonstrating the Group's support for healthcare workers and gratitude for their contributions to public health. The "Long-stay Accommodation Programme" includes seven properties under Regal Hotels: Regal Airport Hotel, Regal Hongkong Hotel, Regal Oriental Hotel, Regal Riverside Hotel, Regala Skycity Hotel, iclub Sheung Wan Hotel and iclub Sheung Wan AMTD Hotel. These hotels are strategically located throughout Hong Kong, featuring excellent transport networks that allow HA employees to save on commuting time. By staying for a minimum of 30 consecutive nights, HA employees can enjoy discounted room rates, as well as services such as room cleaning, free Wi-Fi and self-service laundry facilities. Regal Hotels hopes this program will provide HA employees with comfortable and cost-effective lodging. Rooted in Hong Kong for 45 years, Regal Hotels has been dedicated to providing high-quality accommodation and dining experiences for locals and travellers alike—and this latest initiative marks our ongoing commitment to collaborating with various sectors of society to promote social harmony. The Group has a long history of partnerships with the community, including the recent "YOT Hub" project at Regal Oriental Hotel, developed in partnership with Yan Oi Tong. Ms. Poman Lo, Vice Chairman and Managing Director of Regal Hotels International, stated: "This long-stay accommodation programme for HA reflects our devotion to society and leaving a positive impact on the community. Having observed that the HA has prioritised the recruitment of healthcare personnel to address the rising demands in Hong Kong's public healthcare system, we are committed to exploring solutions to meet societal needs. As one of the largest hotel groups in Hong Kong, we believe that we can provide healthcare practitioners with additional cost-effective accommodation options to cater their housing needs." Regal Hotels will continue to closely monitor social trends, leveraging its comprehensive hotel network and attentive services to extend a helping hand to those in need. Our latest "Long-stay Accommodation Programme" demonstrates our gratitude for the support received from its guests over the years and our commitment to our community. For more information about this long-stay programme, please visit website. Click here to view download high-res hotel room images. Long-stay Accommodation Package for Hospital Authority – Participating Hotels Regal Airport Hotel 9 Cheong Tat Road, Hong Kong International Airport Chek Lap Kok, Lantau Island (852) 2286 8888 Regal Hongkong Hotel 88 Yee Wo Street, Causeway Bay, Hong Kong (852) 2890 6633 Regal Oriental Hotel 30, 38 Sa Po Rd, Kowloon City (852) 2718 0333 Regal Riverside Hotel 34-36 Tai Chung Kiu Road, Shatin, Hong Kong (852) 2649 7878 Regala Skycity Hotel 8 Airport Expo Boulevard, Hong Kong International Airport, Chek Lap Kok, Hong Kong (852) 3556 3288 iclub Sheung Wan Hotel 138 Bonham Strand, Sheung Wan, Hong Kong (852) 3963 6100 iclub Sheung Wan AMTD Hotel 5 Bonham Strand West, Sheung Wan, Hong Kong (852) 3963 6200 About Regal Hotels International: Regal Hotels International (00078) is a member of the Century City Group (00355) which is a conglomerate publicly listed on the Hong Kong Stock Exchange. Regal Hotels International is one of the largest hotel operators in Hong Kong and manages a fine collection of hotels including: Hong Kong – 13. Regal Xindu Hotel (2025) 1. Regal Airport Hotel Chengdu, Sichuan Province – 2. Regal Hongkong Hotel 3. Regal Kowloon Hotel Dezhou, Shandong Province – 4. Regal Oriental Hotel 14. Regal Kangbo Hotel 5. Regal Riverside Hotel 6. Regala Skycity Hotel Shanghai, Shanghai City – 7. iclub Fortress Hill Hotel 15. Regal Jinfeng Hotel 8. iclub To Kwa Wan Hotel 16. Regal Plaza Hotel & Residence 9. iclub Mong Kok Hotel 10. iclub Sheung Wan Hotel 11. iclub AMTD Sheung Wan Hotel 12. iclub Wan Chai Hotel Regal Hotels International also owns the Campus La Mola, located in Barcelona of Spain and The Waterman by Regal, located in London of United Kingdom, which targets to open in 2025.
A12 藝術空間
CheckPoint
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
